Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 5/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 4/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.32 |
| ▸ | CCNB2 | O95067 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 3/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22314882 | 0.83 | — | — | |
| SCHEMBL14417041 | 0.83 | — | — | |
| SCHEMBL3467443 | 0.83 | CDK2 (0.31) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL24029384 | 0.80 | FAAH (0.42) | — | |
| SCHEMBL24867729 | 0.79 | CDK2 (0.33) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL19521626 | 0.77 | CDK2 (0.31) | CDK2CCNE2CCNE1CCNB2CDK1 | |
| SCHEMBL23022602 | 0.75 | — | — | |
| SCHEMBL786579 | 0.73 | — | — | |
| SCHEMBL7080407 | 0.72 | — | — | |
| SCHEMBL15481034 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814384-B2 | Inhibtors of Raf kinases | KINNATE BIOPHARMA INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | BEIJING BAYI SPACE LIQUID CRYSTAL TECHNOLOGY CO. LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| WO-2023150681-A1 | INHIBITORS OF RAF KINASES | KINNATE BIOPHARMA INC. (US) | 2023-08-10 | — | — | WO | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2023-01-26 | — | — | US | disclosed |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-24 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME CORP. | 2010-08-12 | — | — | US | disclosed |
| US-20100168138-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-07-01 | — | — | US | disclosed |
| US-20100160355-A1 | Anti-Viral Compounds | ABBOTT LABORATORIES (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | MERCK SHARP & DOHME LLC | 2010-01-28 | — | — | US | disclosed |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | ALBANY MOLECULAR RESEARCH, INC. | 2010-01-07 | — | — | US | disclosed |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2008-11-13 | — | — | US | disclosed |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | COLLINS IAN J | 2008-03-20 | — | — | US | disclosed |
| US-7282513-B2 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | MERCK SHARP & DOHME LIMITED (GB) | 2007-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168138-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CDK2 113/4885CCNE2 438/4885CCNE1 932/4885 |
| US-20100204236-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | CDK2 4058/4885CCNE2 4784/4885CCNE1 4595/4885 |
| US-20230143250-A1 | 17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 INHIBITORS AND METHODS OF USE THEREOF | HSD17B1, HSD17B13, HSD17B3 | CDK2 2329/4885CCNE2 2843/4885CCNE1 2949/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | CDK2 150/4885CCNE2 129/4885CCNE1 189/4885 |
| US-20100004280-A1 | Substituted imidazoles as bombesin receptor subtype-3 modulators | BRS3, GPR119, GIPR | CDK2 4058/4885CCNE2 4784/4885CCNE1 4595/4885 |
| US-20090197904-A1 | Sulphamides for Treatment of Cancer | SDHA, SDHB, BRDT | CDK2 272/4885CCNE2 315/4885CCNE1 176/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | CDK2 96/4885CCNE2 1312/4885CCNE1 1476/4885 |
| US-20100160355-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | CDK2 113/4885CCNE2 438/4885CCNE1 932/4885 |
| US-20230025630-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | CDK2 4698/4885CCNE2 4837/4885CCNE1 4866/4885 |
| US-20220055998-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK1, CDK13, CDK3 | CDK2 5/4885CCNE2 37/4885CCNE1 43/4885 |
| US-20080280973-A1 | Laulimalide Analogues as Therapeutic Agents | TUBB6, MAN2B1, TUBB1 | CDK2 2698/4885CCNE2 4108/4885CCNE1 2891/4885 |
| US-20080070895-A1 | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase | BACE1, BACE2, PSEN1 | CDK2 1061/4885CCNE2 1369/4885CCNE1 888/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | CDK2 1140/4885CCNE2 2501/4885CCNE1 1903/4885 |
| US-20100022598-A1 | Substituted inmidazoles as bombesin receptor subtype-3 modulators | BRS3, INSR, INSRR | CDK2 3477/4885CCNE2 4780/4885CCNE1 4510/4885 |
| US-11814384-B2 | Inhibtors of Raf kinases | RAF1, BRAF, ARAF | CDK2 85/4885CCNE2 1432/4885CCNE1 864/4885 |
| US-20230348508-A1 | METAL COMPLEX, ORGANIC ELECTROLUMINESCENT ELEMENT COMPRISING SAME, AND CONSUMER PRODUCT | TRPM5, TRPM6, TRPM2 | CDK2 4027/4885CCNE2 1689/4885CCNE1 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.